Why is parity protective for uterine fibroids?

Epidemiology

Volumn 14, Issue 2, 2003, Pages 247-250

  Baird, Donna Day ^a   Dunson, David B ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Involution; Pregnancy; Tissue remodeling; Tumor regression; Uterine leiomyoma

Indexed keywords

ADULT; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; FEMALE; GROWTH INHIBITION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; PARITY; PRIORITY JOURNAL; PUERPERIUM; RISK REDUCTION; SYMPTOMATOLOGY; TISSUE GROWTH; TISSUE REMODELING; TUMOR GROWTH; UTERUS MYOMA; DISEASE PREDISPOSITION; LEIOMYOMA; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATION; RISK FACTOR; UTERUS CANCER;

DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; LEIOMYOMA; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; RISK FACTORS; UTERINE NEOPLASMS;

EID: 0038283997     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-200303000-00021     Document Type: Article

References (41)

1. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 2002;99:229-234.
2. Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM. Uterine leiomyomas. Racial differences in severity, symptoms, and age at diagnosis. J Reprod Med 1996;41:483-489.
3. Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women's Health Study: II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain. Obstet Gynecol 1994;83:566-572.
4. Coronado GD, Marshall LM, Schwartz SM. Complications in pregnancy, labor, and delivery with uterine leiomyomas: a population-based study. Obstet Gynecol 2000;95:764-769.
5. Kempson RL, Hendrickson MR. Smooth muscle, endometrial stromal, and mixed müllerian tumors of the uterus. Mod Path 2000;13:328-342.
6. Townsend DE, Sparkes RS, Baluda MC, McClelland G. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 1970;107:1176-1179.
7. Hashimoto K, Azuma C, Kamiura S, et al. Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phosphoglycerokinase gene. Gynecol Obstet Invest 1995;40:204-208.
8. Fields KR, Neinstein LS. Uterine myomas in adolescents: case reports and a review of the literature. J Pediatr Adolesc Gynecol 1996;9:195-198.
9. Ross RK, Pike M, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ 1986;293:359-362.
10. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94:435-438.
11. Muram D, Gillieson M, Walters JH. Myomas of the uterus in pregnancy: ultrasonographic follow-up. Am J Obstet Gynecol 1980;138:16-19.
12. Lev-Toaff AS, Coleman BG, Arger PH, Mintz MC, Arenson RL, Toaff ME. Leiomyomas in pregnancy: sonographic study. Radiology 1987;164:375-380.
13. Aharoni A, Reiter A, Golan D, Paltiely Y, Sharf M. Patterns of growth of uterine leiomyomas during pregnancy. A prospective longitudinal study. Br J Obstet Gynecol 1988;95:510-513.
14. Rosati P, Exacoustos C, Mancuso S. Longitudinal evaluation of uterine myoma growth during pregnancy: a sonographic study. J Ultrasound Med 1992;11:511-515.
15. Strobelt N, Ghidini A, Cavallone M, Pensabene I, Ceruti P, Vergani P. Natural history of uterine leiomyomas in pregnancy. J Ultrasound Med 1994;13:399-401.
16. Parazzini F, Vecchia CL, Negri E, Cecchetti G, Fedele L. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol 1988;72:853-857.
17. Romieu I, Walker AM, Jick S. Determinants of uterine fibroids. Post Marketing Surveillance 1991;5:119-133.
18. Fedele L, Parazzini F, Luchini L, Mezzopaine R, Tozzi L, Villa L. Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Human Reprod 1995;10:1795-1796.
19. Lumbiganon P, Rugpao S, Phandhu-fung S, Laopaiboon M, Vudhikamraksa N, Werawatakul Y. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study. Br J Obstet Gynaecol 1995;103:909-914.
20. Parazzini F, Negri E, Vecchia CL, Chatenoud L, Ricci E, Guarnerio P. Reproductive factors and risk of uterine fibroids. Epidemiology 1996;7:440-442.
21. Samadi AR, Lee NC, Flanders D, Boring JR III, Parris EB. Risk factors for self-reported uterine fibroids: a case-control study. Am J Public Health 1996;86:858-862.
22. Brett KM, Marsh JV, Madans JH. Epidemiology of hysterectomy in the United States: demographic and reproductive factors in a nationally representative sample. J Womens Health 1997;6:309-316.
23. Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fert Steril 1998;70:432-439.
24. Sato F, Miyake H, Nishi M, Kudo R. Fertility and uterine size among Asian women undergoing hysterectomy for leiomyomas. Int J Fertil 2000;45:34-37.
25. Faerstein E, Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol 2001;153:1-10.
26. Chen C-R, Buck GM, Courey NG, Perez KM, Wactawski-Wende J. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol 2001;153:20-26.
27. Walker CL, Cesen-Cummings K, Houle C, Baird DD, Davis B. Protective effect of pregnancy for development of uterine leiomyoma in Eker rats. Carcinogenesis 2001;22:2049-2052.
28. Szoke B, Kiss D. The use of the ultrasonic echo technique in examining the normal and pathological involution in the puerperium. Int J Gynaecol Obstet 1976;14:513-516.
29. VanRees D, Bernstine RL, Crawford W. Involution of the postpartum uterus: an ultrasonic study. J Clin Ultrasound 1981;9:55-57.
30. Lavery JP, Shaw LA. Sonography of the puerperal uterus. J Ultrasound Med 1989;8:481-486.
31. Wachsberg RH, Krutz AB, Levine CD, Solomon P, Wapner RJ. Real-time ultrasonographic analysis of the normal postpartum uterus: technique, variability, and measurements. J Ultrasound Med 1994;13:215-221.
32. Takamota N, Leppert PC, Yu SY. Cell death and proliferation and its relation to collagen degradation in uterine involution of rat. Connective Tissue Res 1998;37:63-175.
33. Raza SL, Cornelius LA. Matrix metalloproteinases: pro- and antiangiogenic activities. J Invest Dermat Symposium Proc 2000;3:47-54.
34. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481-490.
35. Bergers G, Brekken R, McMahon G, et al Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Boil 2000;2:737-744.
36. Adams WC, Frieden EH. Inhibition of postpartum uterine involution in the rat by relaxin. Biol Reprod 1985;33:1168-1175.
37. Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B, Wagner A, Lauer B, Schuhe-Hermann R. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenisis in rat liver. Proc Natl Acad Sci 1994;91:995-999.
38. Preston GA, Lang JE, Maronpot RR, Barrett JC. Regulation of apoptosis by low serum in cells of different stages of neoplastic progression: enhanced susceptibility after loss of a senescence gene and decreased susceptibility after loss of a tumor suppressor gene. Cancer Res 1994;54:4214-4223.
39. Müllauer L, Grasl-Kraupp B, Bursch W, Schulte-Hermann R. Transforming growth factor β1-induced cell death in preneoplastic foci of rat liver and sensitization by the antiestrogen tamoxifen. Hepatology 1996;23:840-847.
40. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High incidence of uterine liomyoma: ultrasound evidence. Am J Obstet Gynecol, in press.
41. Dunson DB, Baird DD. A proportional hazards model for incidence and induced remission of disease. Biometrics 2002;58:71-78.